The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer.
 
Nai-Jung Chiang
No Relationships to Disclose
 
Jen-Shi Chen
Honoraria - TTY Biopharm
 
Ming-Huang Chen
No Relationships to Disclose
 
Shih-Hung Yang
No Relationships to Disclose
 
Chiun Hsu
No Relationships to Disclose
 
Chia-Jui Yen
Research Funding - PharmaEngine (Inst)
 
Hsiao-Hui Tsou
No Relationships to Disclose
 
Shan Yanshen
Honoraria - PharmaEngine
 
Li-Tzong Chen
Honoraria - Bayer; Lilly; Merck Serono; Novartis; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - BMS Brazil; Lilly; Merrimack; MSD; Ono Pharmaceutical; Shire
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); Taiho Pharmaceutical (Inst); TTY Biopharm (Inst)